Privatdozent Dr. med. Marcel Reiser

Facharzt für Innere Medizin

  • Hämatologie und Internistische Onkologie

 

Vita

geboren 1962 in Köln

Ausbildung und Qualifikation

1984 – 1992 Humanmedizin an der Universität Köln und Zürich
1993 Promotion zum Doktor der Medizin
2001 Facharzt für Innere Medizin
2003 Anerkennung des Schwerpunktes Hämatologie und Internistische Onkologie
2004 Habilitation (Lehrbefugnis für das Fach Innere Medizin an der Uniklinik zu Köln)
2014 Weiterbildungsbefugnis Innere Medizin, Hämatologie und Onkologie

Beruflicher Werdegang

1993 – 1994 Universitätsklinik Köln (Prof. Diehl): Arzt im Praktikum
1994 – 2001 Zentrum Innere Medizin des Klinikums der Universität zu Köln: Ausbildung zum Facharzt für Innere Medizin.
Allgemein-Internistische Behandlung von Erkrankungen aus dem Bereich der gesamten Inneren Medizin einschließlich Hämatologie, Onkologie, Endokrinologie, Immunologie, Gastroenterologie, Nephrologie, Intensivmedizin und Kardiologie.
1999 – 2007 Hauptbefunder im Labor für hämatologischen Labor
ab 2000 Reviewer der Cochrane Gruppe für Hämato-Onkologische Erkrankungen
2002-2008 Facharzt für Innere Medizin in der Klinik I für Innere Medizin, Uniklinik Köln
2006-2008 Oberarzt der Klinik I für Innere Medizin, Uniklinik Köln (Prof. M. Hallek)
1999-2007 Hauptbefunder im Labor für hämatologische Diagnostik, Klinik I für Innere Medizin
2007 Teilanstellung im Medizischen Versorgunszentrum (MVZ) der Uniklinik Köln
2008-2009 ärztlicher Leiter des medizinischen Versorgungszentrum (MVZ) der Uniklinik Köln
2008 Ärztlicher Leiter der MVZ II
seit 2009 Niedergelassener Arzt für Innere Medizin, Hämatologie und Onkologie in Gemeinschaftpraxis mit Frau Dr. Ildiko Kátay
2010 Gründung der überörtlichen Gemeinschaftspraxis PIOH mit den Standorten Frechen und Köln gemeinsam mit Dr. F. Breuer, Privatdozent Dr. R. Schnell, Dr. H. Schulz und Frau Dr. I. Kátay.
2013 Erweiterung der Gemeinschaftspraxis um den Standort Köln-Nord durch Privatdozent Dr. A. Draube.

Forschungsschwerpunkt

Forschungsschwerpunkt sind die malignen Lymphome, insbesondere die Planung und Durchführung von klinischen Studien in den Phasen I-III zur Primär- und Rezidivtherapie bei Patienten mit Non-Hodgkin-Lymphomen, Hodgkin und CLL.
Studien und zahlreiche Publikationen zu Prognosefaktoren maligner Lymphome, T-Zell NHL, ZNS Lymphome und LPHD.

Mitgliedschaften

  • Deutsche Gesellschaft für Hämatologie und Onkologie (DGHO)
  • Deutsche Studiengruppe Hochmaligne Non-Hodgkin Lymphome (DSHNHL)
  • Deutsche CLL-Studiengruppe (DCLLSG)
  • Deutsche Studiengruppe Niedrigmaligne Lymphome (GLSG)
  • Cochrane Gruppe für Hämato-Onkologische Erkrankungen (CHMG)
  • Berufsverband der niedergelassenen Hämatologen und Onkologen Deutschland (BNHO)
  • Berufsverband der niedergelassenen Hämatologen und Onkologen Nordrhein (NIONo)
Publikationen

Verzeichnis der wissenschaftlichen Veröffentlichungen

In referierten Journalen publizierte Originalarbeiten

  • Clinical Lung Cancer Genome Project (CLCGP); Network Genomic Medicine (NGM). A genomics-based classification of human lung tumors. Sci Transl Med. 2013 Oct 30;5(209):209ra153.
  • Steinmetz T, Kuhr K, Totzke U, Hellmich M, Heinz M, Neise M, Mittermüller J, Tessen HW, Reiser M, Severin K, Schmitz S. Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patientsClin Chem Lab Med. 2013 Sep;51(9):1849-57
  • Knauf W, Abenhardt W, Aldaoud A, Nusch A, Grugel R, Münz M, Hartmann H, Marschner N; TLN Study Group. Treatment of Non-transplant patients with multiple myeloma: routine treatment by office-based haematologists in Germany--data from the prospective Tumour Registry Lymphatic Neoplasms (TLN). Oncol Res Treat. 2014;37(11):635-6, 638-44. doi: 10.1159/000368315. Epub 2014 Oct 17. PMID: 25486127.
  • Pfreundschuh M, Müller C, Zeynalova S, Kuhnt E, Wiesen MH, Held G, Rixecker T, Poeschel V, Zwick C, Reiser M, Schmitz N, Murawski N.
    Suboptimal dosing of rituximab in male and female patients with DLBCL.
    Blood. 2014 Jan 30;123(5):640-6. doi: 10.1182/blood-2013-07-517037. Epub 2013 Dec 2.
  • Schildhaus HU, Schultheis AM, Rüschoff J, Binot E, Merkelbach-Bruse S, Fassunke J, Schulte W, Ko YD, Schlesinger A, Bos M, Gardizi M, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Hekmat K, Frank KF, Reiser M, Schulz H, Krüger S, Stoelben E, Zander T, Wolf J, Buettner R
    MET amplification status in therapy-naïve adeno- and squamous cell carcinomas of the lung
    Clin Cancer Res. 2015 Feb 15;21(4):907-15. doi: 10.1158/1078-0432.CCR-14-0450. Epub 2014 Dec 9.
  • Müller D, Fischer K, Kaiser P, Eichhorst B, Walshe R, Reiser M, Kellermann L, Borsi L, Civello D, Mensch A, Bahlo J, Hallek M, Stock S, Fingerle-Rowson G.
    Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia.Leuk Lymphoma. 2016 May;57(5):1130-9. doi: 10.3109/10428194.2015.1070151. Epub 2015 Nov 20.
  • Stangel M, Gold R, Pittrow D, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Reiser M, Sommer C.
    Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registryTher Adv Neurol Disord. 2016 May;9(3):165-79. doi: 10.1177/1756285616629869. Epub 2016 Feb 16.
  • Reiser M, Borte M, Huscher D, Baumann U, Pittrow D, Sommer C, Stangel M, Fasshauer M, Gold R, Hensel M.
    Management of patients with malignancies and secondary immunodeficiencies treated with immunoglobulins in clinical practice: Long-term data of the SIGNS studyEur J Haematol. 2017 Aug;99(2):169-177. doi: 10.1111/ejh.12900. Epub 2017 Jun 21.
  • Bunck A.C. · Pinto dos Santos D. · Chang D.-H. · Reiser M. · Pfister D. · Bunck A. · Drzezga A. · Maintz D. · Schmidt M.
    Successful Yttrium-90 Microsphere Radioembolization for Hepatic Metastases of Prostate
    Cancer Case Rep Oncol 2017;10:627–633
  • Chakupurakal G, Feiten S, Burkhard O, Reiser M, Ehscheidt P, Weide R.
    Successful Evidence-Based Treatment of Patients with Advanced Pancreatic Cancer in Community-Based Oncology Group Practices.
    Oncol Res Treat. 2017;40(12):784-788.
  • Steinmetz HT, Germing U, Sauer A, Lathan B, Liersch R, Tesch H, Heßling J, Moorahrend E, Uhlig J, Reiser M, Wahdat R, Gattermann N, Totzke U, Schmitz S. Myelodysplastic syndromes (MDS) in regular care in Germany - the oldest patients come to the fore.
    Leuk Lymphoma. 2017 Sep 15:1-4.
  • Dührsen U, Broszeit-Luft S, Dieing A, Lück A, Porowski P, Reiser M, Schwinger U, Klawitter S, Krumm K, Jentsch-Ullrich K.
    Rituximab maintenance therapy of follicular lymphoma in clinical practice. Cancer Med. 2018 May 15;7(7):2903–12.
  • Reiser M, Dörfel S, Hensel M, Hoesl M, Jordan WO, Koenigsmann M, Meyer D, Reichert D, Schwarzer A, Marquardt M, Kellershohn K, Jentsch-Ullrich K. Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. Eur J Haematol. 2018
  • Westphalen CB, Kukiolka T, Garlipp B, Hahn L, Fuchs M, Malfertheiner P, Reiser M, Kütting F, Heinemann V, Beringer A, Waldschmidt DT.
    Correlation of skin rash and overall survival in patients with pancreatic cancer treated with gemcitabine and erlotinib - results from a non-interventional multi-center study. BMC Cancer. 2020 Feb 24;20(1):155.
  • Griesinger et al Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
    https://doi.org/10.1016/j.lungcan.2020.10.012
  • M. Reiser, J.G. Kadar, H. Borberg Vergleichende Evaluierung dreier Leukozytenfilter für Thrombozytenkonzentrate. Beitr. Infusionsther, 1991, Vol 28, 216-219.
  • R. Moog, J. Kadar , N. Müller, M. Reiser, T. Weisswange, A.E. Ledermann Biocompatibility studies of the single-needle technique in plateletpheresis with the Fresenius AS 104 blood cell separator. Beitr Infusionsther 1994; 32: 334-338.
  • A. Engert, R. Schnell, F. Küpper, M. Reiser, M. Engelhard, M. Wilhelm, B. Lathan, S. Baltes-Engeler, B. Winterhalter, M.E. Scheulen, B. Dederichs, H. Tesch, B. Wörmann, and V. Diehl A Phase-II Study with idarubicin, ifosfamide and VP-16 (IIVP-16) in Patients with refractory or relapsed agressive and high grade non-Hodgkin´s lymphoma Leukemia Lymphoma 1997; 24: 513-522
  • M. Reiser, G. Fätkenheuer, V. Diehl Paradoxical expansion of intracranial tuberculomas during chemotherapy. Journal of Infection 1997; 35: 88-90.
  • G. Fätkenheuer, A. Theisen, J. Rockstroh, T. Grabow, C. Wicke, K. Becker, U. Wieland, H. Fister, M. Reiser, P. Hegener, C. Franzen, A. Schwenk und B. Salzberger Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS 1997; 11: F113-F116
  • M. Reiser, R. Schnell, G. Straub, M. Wilhelm , R. Übelacker, B. Wörmann, B. Winterhalter, R. Münch, V. Diehl and A. Engert. Dexamethasone, Idarubicin, and continuous infusion of Ifosfamide and VP-16 (DIZE) in relapsed and refractory high-grade non-Hodgkin´s lymphoma and Hodgkin´s disease Leukemia Lymphoma 1998, 31: 359-366
  • M. Reiser, C. Bruns, P. Hartmann, B. Salzberger V. Diehl, G. Fätkenheuer. Raynaud´s Phenomenon and acral necrosis after chemotherapy for AIDS-related Kaposi´s sarcoma. Eur J Clin Microb Inf Dis 1998;17:58-60.
  • M. Reiser, B. Salzberger, A. Stiepel, A. Jütte, R. Hoetelmans, G. Fätkenheuer Pharmacokinetics and Virological Efficacy of Nelfinavir plus Saquinavir as Salvage Therapy in HIV-Infected Patients Refractory to Standard Triple Therapy. Eur J Clin Res, 1999; 4: 54-58
  • M. Reiser, A. Josting, P. Dias Wickramanayake, A. Draube, C. Scheid, H. Tesch, J. Wolf, V. Diehl and A. Engert. Dexa-BEAM is Not Effective in Patients With Relapsed or Resistant Aggressive High-Grade Non-Hodgkin`s Lymphoma. Leukemia Lymphoma, 1999; 33: 305-312
  • D. Re, M. Reiser, S. Bamborschke, R. Schröder, R. Lehrke, H. Tesch, B. Salzberger, V. Diehl, G. Fätkenheuer. Two cases of toxoplasmic encephalitis in patients with acute T-cell leukemia and lymphoma. Journal of Infection, 1999; 38: 26-29
  • C. Scheid, A. Draube, M. Reiser, A. Schulz, J. Chemnitz, S. Nelles, M. Fuchs, S. Winter, P.D. Wickramanayake, V. Diehl, D. Söhngen. Using at least 5x106 CD34+ cells for autologous transplantation significantly reduces febrile complications and the usage of antibiotics after transplantation. Bone Marrow Transpl 1999; 23: 1177-1181
  • M. Reiser, A. Josting, A. Draube, M.Y. Mapara, C. Scheid, J. Chemnitz, H. Tesch, J. Wolf, V. Diehl, D. Söhngen and A. Engert. Successful peripheral blood progenitor cell mobilization with etoposide (VP-16) in patients with relapsed or resistant lymphoma who failed cyclophosphamide mobilization. Bone Marrow Transpl 1999; 23: 1223-1228
  • G. Fätkenheuer, R. M. W. Hoetelmans, N. Hunn, A. Schwenk, C. Franzen, M. Reiser, A. Jütte, J. Rockstroh, V. Diehl, B. Salzberger. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV infected patients. AIDS, 1999; 13:1485-1489
  • M. Reiser, A. Draube, C. Scheid, M. Fuchs, A. Josting, V. Diehl and D. Söhngen High platelet contamination in stem cell concentrates results in significant lower CD34+ yield after immunoselection. Transfusion, 2000; 40: 178-181
  • A. Josting, M. Reiser, P. Dias Wickramanayake, U. Rueffer, A. Draube, D. Söhngen, H. Tesch, J. Wolf, V. Diehl and A. Engert Dexamethasone, carmustine, etoposide, cytarabine, and melphalan (Dexa-BEAM) followed by high-dose chemotherapy and stem cell rescue - A highly effective regimen for patients with refractory or relapsed indolent lymphoma. Leukemia Lymphoma, 2000; 37: 115-123
  • A. Josting, M. Reiser, P. Dias Wickramanayake, U. Rueffer, A. Draube, D. Söhngen, H. Tesch, J. Wolf, V. Diehl and A. Engert Dexa-BEAM: An effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma. Leukemia Lymphoma, 2000; 37: 185-187
  • A. Josting, M. Reiser, B. Salzberger, V. Diehl, A. Engert. Treatment of primary progressive Hodgkin´s and high-grade Non-Hodgkins Lymphoma- Is there a chance for cure? J Clinic Oncol, 2000; 18: 332-339
  • C. Scheid, A,. Draube , M. Reiser, A. Josting, M.Fuchs, J. Chemnitz, S. Winter, A. Schulz, A. Engert, V. Diehl, D. Söhngen. Mobilization with etoposide and G-CSF can replace bone marrow harvesting in patients who have previously failed to mobiliz stem cells with cyclophosphamide and G-CSF. J Hematoth Stem cell 2000; 9(4): 411-413
  • M. Reiser, A. Josting, V. Diehl and A. Engert. Primary lymphoma of the conjunctiva -A rare manifestation of indolent non-Hodgkin´s Lymphoma. Ann Hematol 2001: 80:31-313
  • U.Kaiser, I. Uebelacker, U. Abel, J. Birkmann, L.Trümper, H. Schmalenberg, T. Karakas, B. Metzner, D.K. Hossfeld, H.G. Bischoff, A. Franke, M. Reiser et al. CHOEP(x5) versus CHOEP(x3) followed by early high dose chemotherapy in primary treatment of aggressive Lymphoma-A randomized phase III study. J Clin Oncol. 2002 Nov 15;20(22):4413-9.
  • J. Bohlius, M. Reiser, A. Engert. Impact of prophylactic use of granulopoiesis-stimulating factors (G-CSF and GM-CSF) in patients with malignant lymphoma undergoing conventional chemotherapy: A comprehensive meta-analysis. Brit J Haematol 2003; 122, 1-11.
  • M. Reiser, A. Josting, M. Soltani, P. Staib, B. Salzberger, V. Diehl and A. Engert. T-cell Non-Hodgkin´s lymphoma: Clinical presentation, histology, treatment outcome and prognostic factors of 66 patients treated at a single institution. Leukemia Lymphoma 2002; 43:805-811
  • A. Josting, C. Rudolph, M. Reiser, M. Mapara, M. Sieber, H.H. Kirchner, B. Dörken, D.K. Hossfeld, V. Diehl, A. Engert. Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.Ann Oncol. 2002 Oct;13(10):1628-35.
  • U. Rehwald, H. Schulz, M. Reiser, V.Diehl, A. Engert. Treatment of relapsed CD20-positive Hodgkin´s lymphoma with the monoclonal antibody rituximab is well tolerated and extremely effective Blood. 2003 Jan 15;101(2):420-4.
  • H. Schulz, S. K. Klein, U. Rehwald, M. Reiser, A. Hinke , M. Hallek, W E Aulitzky, M. Hensel, M. Herold, D. Huhn, W. Knauf, V. Diehl A. Engert Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood. 2002 Nov 1;100(9):3115-20.
  • T. Pfitzner, M. Reiser, S. Barth, P. Borchmann, H. Schulz, T. Schinkothe, F. Oberhauser, J. Wessels, M. Tur, V. Diehl , A. Engert . Quantitative molecular monitoring of residual tumor cells in chronic lymphocytic leukemia. Ann Hematol 2002 May;81(5):258-66
  • J. Bohlius, M. Reiser, G. Schwarzer, A. Engert. Granulopoiesis-stimulating factors in the prevention for adverse effects in the therapeutic treatment of malignant lymphoma (Cochrane Review). Cochrane Database Syst Rev. 2002;(4):CD003189.
  • Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma Cochrane Database Syst Rev. 2002;(4):CD003189.
  • M. Pfreundschuh, L. Trümper, M. Kloess, R. Schmits, A.C. Feller, C. Rübe, C. Rudolph,M.Reiser, D. Hossfeld, B. Metzner, D.Hasenclever, B. Glass, N. Schmitz, M. Loeffler 2-weekly or 3-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Young Patients with Good Prognosis (Normal LDH) Aggressive Lymphomas. Results of the NHL-B1 trial of the DSHNHL Blood 2004;104:626-633
  • M. Pfreundschuh, L. Trümper, M. Kloess, R. Schmits, A.C. Feller, C. Rübe, C. Rudolph, M.Reiser, D. Hossfeld, B. Metzner, D.Hasenclever, B. Glass, N. Schmitz, M. Loeffler 2-weekly or 3-Weekly CHOP Chemotherapy with or without Etoposide for the Treatment of Elderly Patients with Aggressive Lymphomas. Results of the NHL-B2 trial of the DSHNHL Blood 2004; 102:634-641
  • A. Wunderlich, M. Kloess, M. Reiser, C. Rudolph, L. Truemper, S. Bittner, H. Schmalenberg, R. Schmits, M. Pfreundschuh, M. Loeffler. German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Practicability and acute haematological toxicity of 2- and 3-weekly CHOP and CHOEP chemotherapy for aggressive non-Hodgkin's lymphoma: results from the NHL-B trial of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol. 2003 Jun;14(6):881-93.
  • A. Rothe, H. Schulz, T. Elter, A. Engert, M. Reiser Rituximab monotherapy is effective in patients with poor risk refractory aggressive non Hodgkin's Lymphoma Haematologica 2004; 89: 857-876
  • Bohlius J, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma Cochrane Database Syst Rev. 2004;(3):CD003189
  • P. Staib, T. Schinköthe, O.Cornely, M. Reiser, C.Schoch, T. Haferlach, V. Diehl Prediction of individual response to chemotherapy in patients with acute myeloid leukemia using the chemosensitivity index Ci Br J Haematol. 2005 Mar;128(6):783-91
  • T. Elter, P. Borchmann, H. Schulz, M. Reiser, M. Jensen, P.Staib, T. Schimköthe, K. Huebel, R. Schnell, A. Josting, A. Engert. Fludarabine in Combination with Alemtuzumab (FluCam) is Effective in Patients with Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia: Results of a Phase II Trial J Clin Oncol. 2005 Oct 1;23(28):7024-31.
  • Dreyling M, Lenz G, Hoster E, Van Hoof A, Gisselbrecht C, Schmits R, Metzner B, Truemper L, Reiser M, Steinhauer H, Boiron JM, Boogaerts MA, Aldaoud A, Silingardi V, Kluin-Nelemans HC, Hasford J, Parwaresch R, Unterhalt M, Hiddemann W. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle cell lymphoma - results of a prospective randomized trial of the European MCL network. Blood. 2005 Apr 1;105(7):2677-84
  • Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R, Reiser M, Metzner B, Harder H, Hegewisch-Becker S, Fischer T, Kropff M, Reis HE, Freund M, Wormann B, Fuchs R, Planker M, Schimke J, Eimermacher H, Trumper L, Aldaoud A, Parwaresch R, Unterhalt M. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the german low grade lymphoma study group (GLSG). Blood. 2005 Aug 25
  • N. Schmitz, M. Kloess, M. Reiser, W. Berdel, B. Metzner, B. Dörken, M. Kneba, L. Trümper, M. Loeffler, M. Pfreundschuh, B. Glass Four or six courses of MegaCHOEP (dose-escalated CHOP plus etoposide) and autologous stem cell transplantation in younger patients with high-risk aggressive lymphoma: A randomized study of the German High-Grade Non-Hodgkin Lymphoma Study Group. Cancer. 2005 Dec 5;
  • Elke Pogge von Strandmann, Hinrich Hansen, Katrin Reiners, Roland Schnell, Peter Borchmann, Sabine Merkert, Andreas Draube, Marcel Reiser, Ingvill Purr and Andreas Engert A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 acticvates a potent NK activity against myeloma cells in vitro and in vivo. Blood. 2005 Oct 6; [Epub ahead of print]
  • Susanne Rödel, Andreas Engert, Volker Diehl, and Marcel Reiser Combination chemotherapy with adriamycin, cyclophosphamide, vincristine, methotrexate, etoposide and dexamethasone (ACOMED) followed by involved field radiotherapy induces high remission rates and durable long term survival in patients with aggressive malignant Non-Hodgkin Lymphomas - Long term follow-up of a pilot study Leukemia and Lymphoma 2005;46: 1729 – 1734
  • Nickenig C., Dreyling M., Hoster E, Pfreundschuh M., Trümper L., Reiser M., Wandt H., Lengfelder E., Ludwig W.-D, Berdel W.E, Metzner B., Forstpointner R., Parwaresch R., Hasford J., Unterhalt M., Hiddemann W. CHOP improves Response Rates but not Survival and has a lower Hematologic Toxicity as compared to MCP in Follicular and Mantle Cell Lymphomas – Results of a Prospective Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) Cancer. 2006 Jul 28
  • Trelle S, Staak JO, Jensen M, Engert A, Reiser M. Implementation and evaluation of a central coordination office for clinical trials in a tertiary care hospital.. Onkologie. 2005 Aug;28(8-9):407-11.
  • Jensen M, Elter T, Engert A, Reiser M. Prolonged remission in a patient with follicular Lymphoma after a single course of Rituximab. Onkologie. 2006 Mar;29(3):90-2
  • M. Zähringer1, J. Hilgers1, K. Krüger1, D. Strohe1, C. Bangard1, L. Neumann1, M. Warm2, M. Reiser3, U. Töx4, K. Lackner1 Die sonographisch gezielte Implantation von Portkathetersystemen über die laterale Vena subclavia. Fortschr Röntgenstr 2006; 178: 324-329
  • Holger Schulz1,2, Julia F. Bohlius1,2, Marcel Reiser1 , Nicole Skoetz1, Sven Trelle1, ,Thilo Kober1, Guido Schwarzer3, Michael Herold4, Martin Dreyling5 , Michael Hallek1 and Andreas Engert Combined Immunochemotherapy With Rituximab Improves Overall Survival in Patients With Indolent Non-Hodgkin lymphoma. Results of a systematic review J Natl Cancer Inst. 2007 May 2;99(9):706-14.
  • Sabine Awerkiew1, Martin Däumer1, Marcel Reiser2, Ulrike C. Wend3, Herbert Pfister1, Rolf Kaiser1, Wulf R. Willems3, Wolfram H. Gerlich3 Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient Journal of Clinical Virology, Volume 38, Issue 1, Pages 83-86
  • Schweighofer CD, Fätkenheuer G, Staib P, Hallek M, Reiser M Lyme disease in a patient with chronic lymphocytic leukemia mimics leukemic meningeosis. Onkologie 2007; 30:564-6
  • Eva Hoster1,2, Martin Dreyling1, Wolfram Klapper3, Christian Gisselbrecht4, Achiel van Hoof5, Hanneke Kluin-Nelemans6, Michael Pfreundschuh7, Michael Hallek8, Claus-Henning Köhne9, Hermann Einsele10, Norma Peter11, Lorenz Trümper12, Bernhard Wörman13, Wolf-Dieter Ludwig14, Ulrich Dührsen15, Hartmut Eimermacher16, Joerg Hasford2, Wolfgang Hiddemann1, Michael Unterhalt1, for the German Low Grade Lymphoma Study Group (GLSG) and the European MCL Network: A New Prognostic Index (MIPI) for Patients with Advanced Stage Mantle Cell Lymphoma Blood. 2008 ;111:558-65.
  • Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke SRecommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin disease J Dtsch Dermatol Ges. 2008 Jan 14
  • Bertram Glass1, Marita Ziepert2, Marcel Reiser3, Mathias Freund4, Lorenz Trümper1, Bernd Metzner5 Alfred Feller6, Markus Loeffler2, Michael Pfreundschuh7, and Norbert Schmitz8 for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) High-dose therapy followed by autologous stem cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma submitted
  • Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trümper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler Six versus Eight Cycles of Bi-weekly CHOP-14 with or without Rituximab for Elderly Patients with Aggressive CD20+ B-Cell Lymphomas Lancet Oncology 2008;9:105-16
  • Annina Herrmann1, Eva Hoster1, Thomas Zwingers2, Günter Brittinger3, Marianne Engelhardt3, Peter Meusers3, Marcel Reiser4, Roswitha Forstpointner1, Bernhard Metzner5, Norma Peter6, Bernhard Wörmann7, Lorenz Trümper8, Michael Pfreundschuh9, Hermann Einsele10, Wolfgang Hiddemann1, Michael Unterhalt1, Martin Dreyling Improvement of Overall Survival in Mantle Cell Lymphoma J Clin Oncol. 2008 Dec 15. [Epub ahead of print]
  • Schulz H, Bohlius J, Skoetz N, Trelle S, Kober T, Reiser M, Dreyling M, Herold M, Schwarzer G, Hallek M, Engert A Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma Cochrane Database Syst Rev. 2007 Oct 17;(4):CD003805
  • Schulz H, Rehwald U, Morschhauser F, Elter T, Driessen C, Rüdiger T, Borchmann P, Schnell R, Diehl V, Engert A, Reiser M. Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG) Blood. 2008;111:109-11.
  • Zwick C, Birkmann J, Peter N, Bodenstein H, Fuchs R, Hänel M, Reiser M, Hensel M, Clemens M, Zeynalova S, Ziepert M, Pfreundschuh M Equitoxicity of bolus and infusional etoposide: results of a multicenter randomised trial of the German High-Grade Non-Hodgkins Lymphoma Study Group (DSHNHL) in elderly patients with refractory or relapsing aggressive non-Hodgkin lymphoma using the CEMP regimen (cisplatinum, etoposide, mitoxantrone and prednisone) Ann Hematol. 2008 Sep;87(9):717-26. Epub 2008 Jun 28.
  • Bohlius J, Herbst C, Reiser M, Schwarzer G, Engert A. Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma. Cochrane Database of Systematic Reviews 2004, Issue 3. Art. No.: CD003189. DOI: 10.1002/14651858.CD003189.pub3.
  • Buske C, Hoster E, Dreyling M, Eimermacher H, Wandt H, Metzner B, Fuchs R, Bittenbring J, Woermann B, Hohloch K, Hess G, Ludwig WD, Schimke J, Schmitz S, Kneba M, Reiser M, Graeven U, Klapper W, Unterhalt M, Hiddemann W The Addition of Rituximab to Front – Line Therapy with CHOP (R-CHOP) Results in a Higher Response Rate and Longer Time to Treatment Failure in Patients with Lymphoplasmacytic Lymphoma – Results of a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) Leukemia. 2008 Sep 25. [Epub ahead of print]
  • Hertl M, Zillikens D, Borradori L, Bruckner-Tuderman L, Burckhard H, Eming R, Engert A, Goebeler M, Hofmann S, Hunzelmann N, Karlhofer F, Kautz O, Lippert U, Niedermeier A, Nitschke M, Pfütze M, Reiser M, Rose C, Schmidt E, Shimanovich I, Sticherling M, Wolff-Franke S. Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases. J Dtsch Dermatol Ges. 2008 May;6(5):366-73. Epub 2008 Jan 14.
  • Eich HT, Heimann M, Stützer H, Kriz J, Reiser M, Müller RP. Strahlenther Onkol. 2009 May;185(5):288-95. Epub 2009 May 15. Long-term outcome and prognostic factors in early-stage nodal low-grade non-hodgkin's lymphomas treated with radiation therapy.
  • Juergens A, Pels H, Rogowski S, Fliessbach K, Glasmacher A, Engert A, Reiser M, Diehl V, Vogt-Schaden M, Egerer G, Schackert G, Reichmann H, Kroschinsky F, Bode U, Herrlinger U, Linnebank M, Deckert M, Fimmers R, Schmidt-Wolf IG, Schlegel U. Long-term survival with favorable cognitive outcome after chemotherapy in primary central nervous system lymphoma Ann Neurol. 2010 Feb;67(2):182-9.
  • Glass B, Ziepert M, Reiser M, Freund M, Trümper L, Metzner B, Feller A, Loeffler M, Pfreundschuh M, Schmitz N; High-dose therapy followed by autologous stem-cell transplantation with and without rituximab for primary treatment of high-risk diffuse large B-cell lymphoma. Ann Oncol. 2010 Nov;21(11):2255-61. Epub 2010 May 5.
  • Kirch W, Gold R, Hensel M, Fasshauer M, Pittrow D, Huscher D, Reiser M, Stangel M, Baumann U, Borte M.: [Assessment of immunoglobulins in a long-term non-interventional study (SIGNS Study). Rationale, design, and methods] Med Klin (Munich). 2010 Sep;105(9):647-51. Epub 2010 Sep 28.
  • Zwick C, Hartmann F, Zeynalova S, Pöschel V, Nickenig C, Reiser M, Lengfelder E, Peter N, Schlimok G, Schubert J, Schmitz N, Loeffler M, Pfreundschuh M Randomized comparison of pegfilgrastim day 4 versus day 2 for the prevention of chemotherapy-induced leukocytopenia Ann Oncol. 2011 Feb 3.
  • Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG; International Primary CNS Lymphoma Collaborative Group (IPCG). Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis Ger Med Sci. 2011;9:Doc11. Epub 2011 May 2.
  • Mueller C Mueller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, Wenger M, Nickenig C, Peter N, Lengfelder E, Metzner B, Rixecker T, Zwick C, Pfreundschuh M, Reiser M. The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. 2012 Apr 5;119(14):3276-84.
  • Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ans√©n S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Huss S, G√∂ke F, Perner S, Hekmat K, Frank KF, Reiser M, Schnell R, Bos M, Mattonet C, Sos M, Stoelben E, Wolf J, Zander T, Buettner R. Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer. Mod Pathol. 2012 Nov;25(11):1473-80.
  • Borte M, Baumann U, Pittrow D, Hensel M, Fasshauer M, Huscher D, Reiser M, Stangel M, Gold R, Kirch W Immunoglobulins in PID, SID and neurological autoimmune disease]. Dtsch Med Wochenschr. 2012 Mar;137(13):675-80.
  • Stangel M, Baumann U, Borte M, Fasshauer M, Hensel M, Huscher D, Kirch W, Pittrow D, Reiser M, Gold R. Treatment of neurological autoimmune diseases with immunoglobulins: first insights from the prospective SIGNS registry. J Clin Immunol. 2013 Jan;33 Suppl 1:S67-71.
  • Witzens-Harig M, Hess G, Atta J, Zaiss M, Lenz G, Scholz C, Repp R, Reiser M, Pott C, Pelz H, La Ros√©e P, Kirchner H, Kiewe P, Keller U, Buske C, Viardot A, Dreyling M. Current treatment of mantle cell lymphoma: results of a national survey and consensus meeting. Ann Hematol. 2012 Nov;91(11):1765-72.
  • Schweighofer CD, Tuchscherer A, Sperka S, Meyer T, Rattel B, Stein S, Ismail S, Elter T, Staib P, Reiser M, Hallek M. Clinical safety and pharmacological profile of the HLA-DR antibody 1D09C3 in patients with B cell chronic lymphocytic leukemia and lymphoma: results from a phase I study. Cancer Immunol Immunother. 2012 Oct 23. [Epub ahead of print]
  • Definition of a fluorescence in-situ hybridization score identifies high- and low-level FGFR1 amplification types in squamous cell lung cancer Schildhaus HU, Heukamp LC, Merkelbach-Bruse S, Riesner K, Schmitz K, Binot E, Paggen E, Albus K, Schulte W, Ko YD, Schlesinger A, Ansén S, Engel-Riedel W, Brockmann M, Serke M, Gerigk U, Huss S, Göke F, Perner S, Hekmat K, Frank KF, Reiser M, Schnell R, Bos M, Mattonet C, Sos M, Stoelben E, Wolf J, Zander T,Buettner,R. Mod Pathol. 2012 Nov;25(11):1473-80
  • Korfel A, Elter T, Thiel E, Hänel M, Möhle R, Schroers R, Reiser M, Dreyling M, Eucker J, Scholz C, Metzner B, Röth A, Birkmann J, Schlegel U, Martus P, Illerhaus G, Fischer L. Phase II study of central nervous system (CNS)-directed chemotherapy including high-dose chemotherapy with autologous stem cell transplantation for CNS relapse of aggressive lymphomas. Haematologica. 2013 Mar;98(3):364-70. Epub 2012 Dec 14.
  • Steinmetz T, Kuhr K, Totzke U, Hellmich M, Heinz M, Neise M, Mittermüller J, Tessen HW, Reiser M, Severin K, Schmitz S. Re-evaluation of laboratory predictors of response to current anemia treatment regimens of erythropoiesis stimulating agents in cancer patientsClin Chem Lab Med. 2013 Sep;51(9):1849-57

Buchartikel

  • M. Reiser, A. Engert, V.Diehl. Time and dose: A crucial factor in high-grade Lymphoma. in ESO scientific Updates, Vol. 3. Dose and timing: The pillars of successful chemotherapy. G. Rosti, editor. 1998 Elsevier Science pp 61-73
  • M. Reiser and V. Diehl. New approaches in the medical treatment of malignant Non-Hodgkin´s lymphoma. ESO Educational book XIII advanced Course of Medical Oncology (Madrid 26. Juni-1.Juli 2001)
  • M. Reiser, A. Engert. Nodale Non-Hodgkin-Lymphome. In Classen, Diehl, Kochsieck, , Berdel, Böhm, Schmiegel, (Hrsg).: Innere Medizin, 5.Auflage 2003 S. 762-766
  • M. Reiser und A. Engert. Non-Hodgkin Lymphome. Medizinische Therapie in Klinik und Praxis.Hrsg J. Schölmerich, 1. Auflage 2003. 369 – 371
  • M. Reiser, A. Engert. Non-Hodgkin-Lymphome. In Classen, Diehl, Kochsieck, , Berdel, Böhm, Schmiegel, (Hrsg).: Innere Medizin, 6.Auflage 2008 S. 139-146
  • M. Reiser Chronisch lymphatische Leukämie In Classen, Diehl, Kochsieck, , Berdel, Böhm, Schmiegel, (Hrsg).: Innere Medizin, 6.Auflage 2008 S. 155-162

Übersichtsartikel

  • M. Reiser, P. Borchmann, V. Diehl, A. Engert. Ifosfamide in the treatment of relapsed lymphoma. Onkologie 1998; 21(Supp. 2:):26-29
  • A. Josting, M. Reiser, V. Diehl. Ovarialkarzinom. Medizin im Bild, 1999; 1:22 - 23
  • A. Engert, A. Josting, M. Reiser, D. Söhngen,V. Diehl. Aktueller Stellenwert der Hochdosistherapie in der Hämatologie und internistischen Onkologie . Medizinische Klinik 1999; 94:431-442.
  • M. Reiser, H. Bredenfeld, A. Engert, V. Diehl. The role of Ifosfamid in the treatment of relapsed and refractory lymphoma. Eur J Haematol 2001: 66 (Suppl.1):36-40.
  • M. Reiser, Diehl V. Current treatment of follicular Non-Hodgkin´s lymphoma. E J Cancer 2002;38:1167-1172
  • P. Borchmann, M. Reiser Pixantrone Novuspharma Idrugs 2003; 6: 486-490
  • Held G., Schubert J, Reiser M, Pfreundschuh M. DOSE-INTENSIFIED TREATMENT OF ADVANCED STAGE DIFFUSE LARGE B-CELL LYMPHOMAS Semin Hematol. 2006 Oct;43(4):221-9.
  • P. Borchmann, B. Eichhorst, M. Hellmann, K. Hübel, M. Kochaneck, K. Kreuzer, M. Reiser, M. Hallek. Hämatologie 2008 Dtsch Med Wochenschr 2008; 133:1400-1404

PD Dr. med. Marcel Reiser

Facharzt für Innere Medizin, Hämatologie, Onkologie
© 2020 pioh frechen, pioh köln zentrum, pioh köln nord